Exosomes are extracellular vesicles 40 to 160 nm in diameter that mainly mediate information transmission and substance exchange between cells, and increasing evidence suggests that exosomes are involved in the development of tumors and have great potential in cancer diagnosis and treatment. Squamous cell carcinoma of head and neck is one of the common malignant tumors in the whole body. Although various treatments continue to develop, the 5-year survival rate remains only 50%, which may be related to its characteristics such as easy lymphatic metastasis, chemotherapy resistance and poor radiotherapy sensitivity. Researchers are paying more and more attention to TDE, and studies connected to it have significantly improved our understanding of the causes, development, diagnosis, and prognosis of HNSCC. Head and neck squamous cell carcinoma-derived exosomes involve tumor initiation, progression, immune regulation, diagnosis and treatment application, and are anticipated to serve as therapeutic targets and biomarkers for early tumor diagnosis, and new ideas for improving the survival rate and prognosis of patients with head and neck squamous cell carcinoma are provided by their related studies. Here, in order to bring our knowledge of exosomes derived from head and neck squamous cell carcinoma up to date, we examine the development of research on tumor-derived exosomes in the disease.
Published in | Cancer Research Journal (Volume 11, Issue 1) |
DOI | 10.11648/j.crj.20231101.14 |
Page(s) | 28-33 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2023. Published by Science Publishing Group |
Head and Neck Squamous Cell Carcinoma, Tumor-Derived Exosomes, miRNAs, Proteins
[1] | Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primer 2020; 6: 92. doi: 10.1038/s41572-020-00224-3. |
[2] | Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin 2021; 71: 7–33. doi: 10.3322/caac.21654. |
[3] | Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science 2020; 367: eaau6977. doi: 10.1126/science.aau6977. |
[4] | Chulpanova DS, Kitaeva KV, James V, et al. Therapeutic Prospects of Extracellular Vesicles in Cancer Treatment. Front Immunol 2018; 9: 1534. doi: 10.3389/fimmu.2018.01534. |
[5] | Xiao C, Song F, Zheng YL, et al. Exosomes in Head and Neck Squamous Cell Carcinoma. Front Oncol 2019; 9: 894. doi: 10.3389/fonc.2019.00894. |
[6] | Fitts CA, Ji N, Li Y, et al. Exploiting Exosomes in Cancer Liquid Biopsies and Drug Delivery. Adv Healthc Mater 2019; 8: e1801268. doi: 10.1002/adhm.201801268. |
[7] | Hofmann L, Ludwig S, Schuler PJ, et al. The Potential of CD16 on Plasma-Derived Exosomes as a Liquid Biomarker in Head and Neck Cancer. Int J Mol Sci 2020; 21: E3739. doi: 10.3390/ijms21113739. |
[8] | Theodoraki M-N, Matsumoto A, Beccard I, et al. CD44v3 protein-carrying tumor-derived exosomes in HNSCC patients’ plasma as potential noninvasive biomarkers of disease activity. Oncoimmunology 2020; 9: 1747732. doi: 10.1080/2162402X.2020.1747732. |
[9] | Sanada T, Islam A, Kaminota T, et al. Elevated exosomal lysyl oxidase like 2 is a potential biomarker for head and neck squamous cell carcinoma. The Laryngoscope 2020; 130: E327–E334. doi: 10.1002/lary.28142. |
[10] | Nakamichi E, Sakakura H, Mii S, et al. Detection of serum/salivary exosomal Alix in patients with oral squamous cell carcinoma. Oral Dis 2021; 27: 439–447. doi: 10.1111/odi.13565. |
[11] | Li C, Zhou Y, Liu J, et al. Potential Markers from Serum-Purified Exosomes for Detecting Oral Squamous Cell Carcinoma Metastasis. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 2019; 28: 1668–1681. doi: 10.1158/1055-9965.EPI-18-1122. |
[12] | Qu X, Leung TCN, Ngai S-M, et al. Proteomic Analysis of Circulating Extracellular Vesicles Identifies Potential Biomarkers for Lymph Node Metastasis in Oral Tongue Squamous Cell Carcinoma. Cells 2021; 10: 2179. doi: 10.3390/cells10092179. |
[13] | Wang J, Zhou Y, Lu J, et al. Combined detection of serum exosomal miR-21 and HOTAIR as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma. Med Oncol Northwood Lond Engl 2014; 31: 148. doi: 10.1007/s12032-014-0148-8. |
[14] | Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer - PMC. Im Internet: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581802/; Stand: 31.03.2022 |
[15] | Langevin S, Kuhnell D, Parry T, et al. Comprehensive microRNA-sequencing of exosomes derived from head and neck carcinoma cells in vitro reveals common secretion profiles and potential utility as salivary biomarkers. Oncotarget 2017; 8: 82459–82474. doi: 10.18632/oncotarget.19614. |
[16] | Coon J, Kingsley K, Howard KM. miR-365 (microRNA): Potential Biomarker in Oral Squamous Cell Carcinoma Exosomes and Extracellular Vesicles. Int J Mol Sci 2020; 21: E5317. doi: 10.3390/ijms21155317. |
[17] | Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL. Clinical significance of PD-L1+ exosomes in plasma of Head and Neck Cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2018; 24 (4): 896-905. doi: 10.1158/1078-0432.CCR-17-2664. |
[18] | Theodoraki MN, Hoffmann TK, Jackson EK, Whiteside TL. Exosomes in HNSCC plasma as surrogate markers of tumour progression and immune competence. Clin Exp Immunol. 2018; 194 (1): 67-78. doi: 10.1111/cei.13157. |
[19] | Ludwig S, Marczak L, Sharma P, et al. Proteomes of exosomes from HPV(+) or HPV(-) head and neck cancer cells: differential enrichment in immunoregulatory proteins. Oncoimmunology 2019; 8: 1593808. doi: 10.1080/2162402X.2019.1593808. |
[20] | Pang X, Wang S-S, Zhang M, et al. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway. Cancer Immunol Immunother CII 2021; 70: 1015–1029. doi: 10.1007/s00262-020-02741-2. |
[21] | Xiao M, Zhang J, Chen W, et al. M1-like tumor-associated macrophages activated by exosome-transferred THBS1 promote malignant migration in oral squamous cell carcinoma. J Exp Clin Cancer Res CR 2018; 37: 143. doi: 10.1186/s13046-018-0815-2. |
[22] | Ludwig N, Yerneni SS, Razzo BM, et al. Exosomes from HNSCC Promote Angiogenesis through Reprogramming of Endothelial Cells. Mol Cancer Res MCR 2018; 16: 1798–1808. doi: 10.1158/1541-7786.MCR-18-0358. |
[23] | Głuszko A, Szczepański MJ, Whiteside TL, et al. Small Extracellular Vesicles from Head and Neck Squamous Cell Carcinoma Cells Carry a Proteomic Signature for Tumor Hypoxia. Cancers 2021; 13: 4176. doi: 10.3390/cancers13164176. |
[24] | Zhao Q, Zheng X, Guo H, et al. Serum Exosomal miR-941 as a promising Oncogenic Biomarker for Laryngeal Squamous Cell Carcinoma. J Cancer. 2020; 11 (18): 5329-5344. doi: 10.7150/jca.45394. |
[25] | Yan W, Wang Y, Chen Y, et al. Exosomal miR-130b-3p Promotes Progression and Tubular Formation Through Targeting PTEN in Oral Squamous Cell Carcinoma. Front Cell Dev Biol 2021; 9: 616306. doi: 10.3389/fcell.2021.616306. |
[26] | He S, Zhang W, Li X, et al. Oral squamous cell carcinoma (OSCC)-derived exosomal MiR-221 targets and regulates phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) to promote human umbilical vein endothelial cells migration and tube formation. Bioengineered 2021; 12: 2164–2174. doi: 10.1080/21655979.2021.1932222. |
[27] | Exosome-derived microRNAs in oral squamous cell carcinomas impact disease prognosis - PubMed. Im Internet: https://pubmed.ncbi.nlm.nih.gov/34174519/; Stand: 09.04.2022 |
[28] | Zhou S, Zhu Y, Li Z, et al. Exosome-derived long non-coding RNA ADAMTS9-AS2 suppresses progression of oral submucous fibrosis via AKT signalling pathway. J Cell Mol Med 2021; 25: 2262–2273. doi: 10.1111/jcmm.16219. |
[29] | Luo Y, Liu F, Guo J, et al. Upregulation of circ_0000199 in circulating exosomes is associated with survival outcome in OSCC. Sci Rep 2020; 10: 13739. doi: 10.1038/s41598-020-70747-y. |
[30] | Ludwig N, Gillespie DG, Reichert TE, et al. Purine Metabolites in Tumor-Derived Exosomes May Facilitate Immune Escape of Head and Neck Squamous Cell Carcinoma. Cancers 2020; 12: E1602. doi: 10.3390/cancers12061602. |
[31] | Li S, Shi Z, Fu S, et al. Exosomal-mediated transfer of APCDD1L-AS1 induces 5-fluorouracil resistance in oral squamous cell carcinoma via miR-1224-5p/nuclear receptor binding SET domain protein 2 (NSD2) axis. Bioengineered 2021; 12: 7188–7204. doi: 10.1080/21655979.2021.1979442. |
[32] | Sayyed AA, Gondaliya P, Mali M, et al. MiR-155 Inhibitor-Laden Exosomes Reverse Resistance to Cisplatin in a 3D Tumor Spheroid and Xenograft Model of Oral Cancer. Mol Pharm 2021; 18: 3010–3025. doi: 10.1021/acs.molpharmaceut.1c00213. |
[33] | Tong F, Mao X, Zhang S, et al. HPV + HNSCC-derived exosomal miR-9 induces macrophage M1 polarization and increases tumor radiosensitivity. Cancer Lett 2020; 478: 34–44. doi: 10.1016/j.canlet.2020.02.037. |
[34] | Wu P, Fang X, Liu Y, et al. N6-methyladenosine modification of circCUX1 confers radioresistance of hypopharyngeal squamous cell carcinoma through caspase1 pathway. Cell Death Dis 2021; 12: 298. doi: 10.1038/s41419-021-03558-2. |
[35] | Fujiwara T, Eguchi T, Sogawa C, et al. Carcinogenic epithelial-mesenchymal transition initiated by oral cancer exosomes is inhibited by anti-EGFR antibody cetuximab. Oral Oncol 2018; 86: 251–257. doi: 10.1016/j.oraloncology.2018.09.030. |
[36] | Kase Y, Uzawa K, Wagai S, et al. Engineered exosomes delivering specific tumor-suppressive RNAi attenuate oral cancer progression. Sci Rep 2021; 11: 5897. doi: 10.1038/s41598-021-85242-1. |
[37] | Theodoraki M-N, Yerneni S, Gooding WE, et al. Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT. Oncoimmunology 2019; 8: 1593805. doi: 10.1080/2162402X.2019.1593805. |
APA Style
Wenmin Zhao, Feng Yu. (2023). Progress of Tumor-Derived Exosomes in Head and Neck Squamous Cell Carcinoma. Cancer Research Journal, 11(1), 28-33. https://doi.org/10.11648/j.crj.20231101.14
ACS Style
Wenmin Zhao; Feng Yu. Progress of Tumor-Derived Exosomes in Head and Neck Squamous Cell Carcinoma. Cancer Res. J. 2023, 11(1), 28-33. doi: 10.11648/j.crj.20231101.14
AMA Style
Wenmin Zhao, Feng Yu. Progress of Tumor-Derived Exosomes in Head and Neck Squamous Cell Carcinoma. Cancer Res J. 2023;11(1):28-33. doi: 10.11648/j.crj.20231101.14
@article{10.11648/j.crj.20231101.14, author = {Wenmin Zhao and Feng Yu}, title = {Progress of Tumor-Derived Exosomes in Head and Neck Squamous Cell Carcinoma}, journal = {Cancer Research Journal}, volume = {11}, number = {1}, pages = {28-33}, doi = {10.11648/j.crj.20231101.14}, url = {https://doi.org/10.11648/j.crj.20231101.14}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20231101.14}, abstract = {Exosomes are extracellular vesicles 40 to 160 nm in diameter that mainly mediate information transmission and substance exchange between cells, and increasing evidence suggests that exosomes are involved in the development of tumors and have great potential in cancer diagnosis and treatment. Squamous cell carcinoma of head and neck is one of the common malignant tumors in the whole body. Although various treatments continue to develop, the 5-year survival rate remains only 50%, which may be related to its characteristics such as easy lymphatic metastasis, chemotherapy resistance and poor radiotherapy sensitivity. Researchers are paying more and more attention to TDE, and studies connected to it have significantly improved our understanding of the causes, development, diagnosis, and prognosis of HNSCC. Head and neck squamous cell carcinoma-derived exosomes involve tumor initiation, progression, immune regulation, diagnosis and treatment application, and are anticipated to serve as therapeutic targets and biomarkers for early tumor diagnosis, and new ideas for improving the survival rate and prognosis of patients with head and neck squamous cell carcinoma are provided by their related studies. Here, in order to bring our knowledge of exosomes derived from head and neck squamous cell carcinoma up to date, we examine the development of research on tumor-derived exosomes in the disease.}, year = {2023} }
TY - JOUR T1 - Progress of Tumor-Derived Exosomes in Head and Neck Squamous Cell Carcinoma AU - Wenmin Zhao AU - Feng Yu Y1 - 2023/03/31 PY - 2023 N1 - https://doi.org/10.11648/j.crj.20231101.14 DO - 10.11648/j.crj.20231101.14 T2 - Cancer Research Journal JF - Cancer Research Journal JO - Cancer Research Journal SP - 28 EP - 33 PB - Science Publishing Group SN - 2330-8214 UR - https://doi.org/10.11648/j.crj.20231101.14 AB - Exosomes are extracellular vesicles 40 to 160 nm in diameter that mainly mediate information transmission and substance exchange between cells, and increasing evidence suggests that exosomes are involved in the development of tumors and have great potential in cancer diagnosis and treatment. Squamous cell carcinoma of head and neck is one of the common malignant tumors in the whole body. Although various treatments continue to develop, the 5-year survival rate remains only 50%, which may be related to its characteristics such as easy lymphatic metastasis, chemotherapy resistance and poor radiotherapy sensitivity. Researchers are paying more and more attention to TDE, and studies connected to it have significantly improved our understanding of the causes, development, diagnosis, and prognosis of HNSCC. Head and neck squamous cell carcinoma-derived exosomes involve tumor initiation, progression, immune regulation, diagnosis and treatment application, and are anticipated to serve as therapeutic targets and biomarkers for early tumor diagnosis, and new ideas for improving the survival rate and prognosis of patients with head and neck squamous cell carcinoma are provided by their related studies. Here, in order to bring our knowledge of exosomes derived from head and neck squamous cell carcinoma up to date, we examine the development of research on tumor-derived exosomes in the disease. VL - 11 IS - 1 ER -